| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
The traditional Japanese herbal medicine boiogito (BOT) is clinically used for patients who have osteoarthritis with accompanying inflammation. However, pharmacological evidence for its antinociceptive effects in vivo remains unclear. BOT contains the morphinan alkaloid sinomenine, which is thought to be a principle active constituent. The antinociceptive activity of BOT extract and sinomenine were evaluated using typical nociceptive models: the hot-plate, formalin test and Seltzer model. BOT showed antinociceptive activities against three different types of pain models. Sinomenine also suppressed nociception induced by three different pain. The opioid antagonist naloxone did not reverse the antinociceptive effects of sinomenine. The nociception mechanisms in response to sinomenine occur via an opioid receptor-independent pathway. Thus, BOT and sinomenine are clinically useful to alleviate pain.
|
